Navigation Links
Dartmouth researchers test safety of Nivolumab in kidney cancer
Date:6/3/2013

(Lebanon, NH, 5/24/13) Researchers at Dartmouth-Hitchcock Norris Cotton Cancer Center will present a poster on a phase I clinical trial of Nivolumab, a PD-1 receptor blocking antibody, being used in combination with other drugs in patients with metastatic renal cell carcinoma (mRCC) at the ASCO Annual Meeting on June 3, 2013.

Metastatic renal cell carcinoma or kidney cancer is the seventh most common cancer, leading to approximately 116,000 deaths annually worldwide. In roughly one-quarter of those with mRCC, the cancer has already spread or metastasized at diagnosis.

Nivolumab is an immune checkpoint inhibitor being tested in many cancers such as advanced melanoma and nonsmall cell lung cancer. It helps the body fight renegade cancer cells by restoring normal T-cell antitumor function. T-cells are a type of white blood cell that act like soldiers by searching out and destroying invaders. Nivolumab accomplishes this by suppressing an immune checkpoint modulator.

In this study, Nivolumab will be used in combination with sunitinib, pazopanib (existing treatments), or ipilimumab. These existing treatments have shown to reduce progression of the disease, but without lasting or durable response. Many patients eventually develop resistance to them. In other Phase 1 and 2 clinical trials, Nivolumab has shown durable responses in patients with mRCC.

The ASCO poster session describes an ongoing four-arm Phase 1 dose-escalation and expansion study evaluating combinations of Nivolumab with sunitinib, pazopanib, or ipilimumab in patients with mRCC. The primary objectives are to assess safety and tolerability, and to determine the recommended Phase 2 dose in patients with mRCC. The secondary objective is to assess preliminary antitumor activity. Researchers will also evaluate overall survival, pharmacodynamics, predictive biomarkers for the combinations, pharmacokinetics and immunogenicity of Nivolumab.


'/>"/>

Contact: Donna Dubuc
donna.m.dubuc@hitchcock.org
603-653-3615
Dartmouth-Hitchcock Medical Center
Source:Eurekalert

Page: 1

Related medicine news :

1. Dartmouth researchers investigate the cognitive effects of athlete head impacts
2. Mayo Clinic, Dartmouth-Hitchcock announce collaboration
3. Dartmouth medical research closes in on new tuberculosis vaccine
4. Leap in leukemia treatment reported by Dartmouth researchers
5. NIH awards $20 million over 5 years to train next generation of global health researchers
6. Researchers develop a new cell and animal model of inflammatory breast cancer
7. Researchers uncover a viable way for colorectal cancer patients to overcome drug resistance
8. Researchers Find Gene Mutations That May Be a Key to Autism
9. Researchers find evidence of banned antibiotics in poultry products
10. NJ stroke researchers report advances in spatial neglect research at AAN Conference
11. Autism by the numbers: Yale researchers examine impact of new diagnostic criteria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... May 26, 2017 , ... Somnoware, a leading provider of ... with its Somnoware Sleep Device Interface (SDI). Somnoware SDI is a sleep device ... this platform, initializing devices and importing studies are just one-click operations. This plugin ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... is sharing bold recipes for Memorial Day entertaining that are sure to satisfy ... “Boar’s Head fresh sliced meats and cheeses featured in these refreshingly balanced recipes ...
(Date:5/26/2017)... BOSTON, MA (PRWEB) , ... May 26, 2017 , ... ... Care Act (AHCA), which narrowly passed the U.S. House on May 4, would result ... would be expected under continued implementation of the 2010 Patient Protection and Affordable Care ...
(Date:5/26/2017)... ... May 26, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... week that is focusing on the Peace Agreements being discussed by President Donald Trump ... in a race to try to speed up peace talks in the continuous battle ...
(Date:5/26/2017)... ... ... Rob Lowe acts as host and helps educate and inform the public using ... Viewers can reconnect with America as it explores some of the best places to ... for an inventive new place for a family vacation, and have discovered hiking. Many ...
Breaking Medicine News(10 mins):
(Date:5/18/2017)... 17, 2017  Bayer announced today that the latest ... presented at the 53 rd Annual Meeting of ... June 2-6 in Chicago . ... prostate, colorectal, liver and thyroid cancers, as well as ... II CHRONOS-1 trial of copanlisib in patients with relapsed ...
(Date:5/15/2017)... Inc., a privately-held CNS pharmaceutical company based in ... disease (PD), has enrolled the first patient in the RASMET ... study involving patients with PD and taking place at 12 ... period. The first stage is open label and involves single ... Denver , Boca Raton ...
(Date:5/11/2017)... 11, 2017  Thornhill Research Inc. ( ... an $8,049,024 USD five-year, firm-fixed-priced, indefinite-quantity/indefinite-delivery contract by ... Commercial Corporation (CCC) ( Ottawa, Ontario, Canada ... administer general anesthesia to patients requiring emergency medical ... US Marine Corps have been a longtime partner ...
Breaking Medicine Technology: